SG Americas Securities LLC Has $405,000 Holdings in Kura Oncology, Inc. $KURA

SG Americas Securities LLC cut its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 67.2% during the 1st quarter, Holdings Channel reports. The firm owned 49,816 shares of the company’s stock after selling 101,899 shares during the period. SG Americas Securities LLC’s holdings in Kura Oncology were worth $405,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KURA. State Street Corp grew its position in Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after buying an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Kura Oncology by 111.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after acquiring an additional 965,256 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Kura Oncology by 36.6% during the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after acquiring an additional 820,020 shares during the period. Finally, Qube Research & Technologies Ltd lifted its position in shares of Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after acquiring an additional 738,761 shares during the period.

Analyst Ratings Changes

KURA has been the topic of several analyst reports. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a report on Thursday, May 28th. Mizuho cut their price objective on shares of Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. CLSA set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Lake Street Capital assumed coverage on shares of Kura Oncology in a research note on Tuesday, April 14th. They set a “buy” rating and a $23.00 price objective on the stock. Finally, Oppenheimer set a $24.00 target price on shares of Kura Oncology in a report on Thursday, May 28th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.46.

Kura Oncology Stock Down 0.3%

NASDAQ KURA opened at $12.08 on Friday. The business has a fifty day moving average price of $9.94 and a two-hundred day moving average price of $9.25. The stock has a market capitalization of $1.07 billion, a PE ratio of -3.61 and a beta of 0.35. Kura Oncology, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The company had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Equities analysts expect that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This trade represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 7.60% of the stock is owned by company insiders.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.